Table 2.
Use of combined menopausal hormone therapy in cases and controls
| Cases of all cause dementia (n=5589) |
Controls (n=55 890) |
P value | |
|---|---|---|---|
| Ever users of oestrogen-progestin | 1782 (31.9) | 16 154 (28.9) | |
| Age at initiation of use, years: | |||
| Median (interquartile range) | 53 (50-54) | 53 (50-54) | |
| 45-49 | 331 (18.6) | 2714 (16.8) | 0.31 |
| 50-54 | 1084 (60.8) | 10 051 (62.2) | |
| 55-59 | 354 (19.9) | 3271 (20.2) | |
| ≥60 | 13 (0.7) | 118 (0.7) | |
| Duration of use, years: | |||
| ≤1 | 447 (25.1) | 4043 (25.0) | <0.001 |
| >1-4 | 460 (25.8) | 4397 (27.2) | |
| >4-8 | 447 (25.1) | 4468 (27.7) | |
| >8-12 | 282 (15.8) | 2311 (14.3) | |
| >12 | 146 (8.2) | 935 (5.8) | |
| Method of treatment: | |||
| Continuous progestin | 458 (25.7) | 3919 (24.3) | 0.49 |
| Cyclic progestin | 694 (38.9) | 6284 (38.9) | |
| Continuous and cyclic oestrogen and progestin | 542 (30.4) | 5096 (31.5) | |
| Unknown | 88 (4.9) | 855 (5.3) | |
| Route of administration: | |||
| Oral administration only | 1609 (90.3) | 14 391 (89.1) | 0.07 |
| Transdermal administration only | 56 (3.1) | 462 (2.9) | |
| Mixed or other administration | 117 (6.6) | 1301 (8.1) | |
| Active ingredients: | |||
| Oestradiol+norethisterone | 1488 (83.5) | 13 024 (80.6) | 0.004 |
| Oestradiol+medroxyprogesterone | 525 (29.5) | 5134 (31.8) | 0.05 |
| Oestradiol+levonorgestrel | 137 (7.7) | 1557 (9.6) | 0.009 |
| Oestradiol+cyproterone | 77 (4.3) | 874 (5.4) | 0.06 |
| Oestradiol+dienogest | 40 (2.2) | 270 (1.7) | 0.10 |
Column percentages are no of ever users of oestrogen-progestin.